Online inquiry

IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1417MR)

This product GTTS-WQ1417MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_024690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94025
UniProt ID Q8WXI7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1417MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3975MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ4859MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ9698MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ13150MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ3601MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ6731MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ13145MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ7490MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW